Gilead Sciences, Inc.
GILD
$97.03
-$1.13-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.73B | 28.75B | 28.30B | 27.80B | 27.45B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.73B | 28.75B | 28.30B | 27.80B | 27.45B |
| Cost of Revenue | 6.24B | 6.25B | 6.28B | 6.27B | 6.17B |
| Gross Profit | 22.50B | 22.50B | 22.02B | 21.53B | 21.28B |
| SG&A Expenses | 5.86B | 6.00B | 5.72B | 5.63B | 6.11B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.81B | 18.09B | 17.66B | 17.62B | 18.05B |
| Operating Income | 10.93B | 10.66B | 10.64B | 10.19B | 9.40B |
| Income Before Tax | 6.83B | 691.00M | 177.00M | 1.54B | 1.08B |
| Income Tax Expenses | 860.00M | 211.00M | 63.00M | 506.00M | 617.00M |
| Earnings from Continuing Operations | 5.97K | 480.00 | 114.00 | 1.03K | 458.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 12.00M | 20.00M | 26.00M |
| Net Income | 5.97B | 480.00M | 126.00M | 1.05B | 484.00M |
| EBIT | 10.93B | 10.66B | 10.64B | 10.19B | 9.40B |
| EBITDA | 13.70B | 13.43B | 13.40B | 12.94B | 12.15B |
| EPS Basic | 4.78 | 0.38 | 0.10 | 0.84 | 0.38 |
| Normalized Basic EPS | 5.12 | 5.00 | 5.00 | 4.81 | 4.44 |
| EPS Diluted | 4.74 | 0.35 | 0.08 | 0.81 | 0.35 |
| Normalized Diluted EPS | 5.09 | 4.98 | 4.98 | 4.79 | 4.42 |
| Average Basic Shares Outstanding | 4.99B | 4.99B | 4.99B | 4.99B | 4.99B |
| Average Diluted Shares Outstanding | 5.02B | 5.01B | 5.01B | 5.01B | 5.02B |
| Dividend Per Share | 3.10 | 3.08 | 3.06 | 3.04 | 3.02 |
| Payout Ratio | 66.02% | 816.25% | 3,085.71% | 366.38% | 791.32% |